| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Cereblon
CRBN (cereblon), an E3 ubiquitin ligase. |
|---|---|
| ln Vitro |
As a cereblon-binding ligand, Thalidomide-O-C8-COOH itself has no intrinsic biological activity; its function is to bind to CRBN and recruit the E3 ubiquitin ligase complex. The terminal carboxylic acid is conjugated to a target protein ligand via a linker, and the resulting PROTAC can ubiquitinate and degrade the target protein via the proteasome.
|
| ln Vivo |
No specific in vivo activity has been reported for this ligand alone; its in vivo degradation activity is observed only when conjugated to a target protein ligand to form a complete PROTAC molecule. The in vivo efficacy of such a PROTAC is typically evaluated in animal models.
|
| Enzyme Assay |
N/A; as a ligand, its binding affinity to cereblon is typically determined using biophysical methods such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) as part of the validation of the final PROTAC construct. The terminal carboxylic acid enables standard amide coupling chemistry.
|
| Cell Assay |
N/A; this ligand is not evaluated alone in cell-based assays but is used as a building block to construct cereblon-recruiting PROTACs for cellular degradation studies. In a typical conjugation step, the terminal carboxylic acid is activated with EDC and NHS and coupled to a primary amine-containing linker, which is then attached to a target protein ligand.
|
| Animal Protocol |
N/A; no animal studies are performed with the ligand alone. In vivo efficacy studies would be conducted using the complete PROTAC molecule synthesized from this building block. The extended C8 linker provides optimal spatial flexibility for ternary complex formation.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 430.45, a molecular formula of C22H26N2O7, and appears as a white to off-white solid powder. It is typically stored as a powder at -20degC for up to 3 years or in a solvent at -80degC for 6 months. It is soluble in DMSO (140 mg/mL, 325.24 mM). The IUPAC name is 9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxynonanoic acid. LogP is 2.5.
|
| Toxicity/Toxicokinetics |
This product is for research and manufacturing use only and is not for human or clinical use. Standard chemical safety precautions should be followed during handling. The product should be stored under nitrogen and protected from moisture.
|
| References | |
| Additional Infomation |
The extended eight-carbon (C8) alkyl spacer provides added spatial flexibility, improving the range of target engagement in heterobifunctional degrader synthesis. The terminal carboxylic acid allows for versatile conjugation strategies. This ligand is ideal for drug discovery, chemical biology, and therapeutic design, helping researchers develop selective and potent PROTAC molecules for studying and modulating disease-relevant proteins.
|
| Molecular Formula |
C22H26N2O7
|
|---|---|
| Molecular Weight |
430.451046466827
|
| Exact Mass |
430.174
|
| CAS # |
2225148-51-4
|
| PubChem CID |
139433330
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
31
|
| Complexity |
723
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCCCCCCCCC(=O)O
|
| InChi Key |
JDVPWEYIVOQCDX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H26N2O7/c25-17-12-11-15(20(28)23-17)24-21(29)14-8-7-9-16(19(14)22(24)30)31-13-6-4-2-1-3-5-10-18(26)27/h7-9,15H,1-6,10-13H2,(H,26,27)(H,23,25,28)
|
| Chemical Name |
9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxynonanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~140 mg/mL (~325.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3232 mL | 11.6158 mL | 23.2315 mL | |
| 5 mM | 0.4646 mL | 2.3232 mL | 4.6463 mL | |
| 10 mM | 0.2323 mL | 1.1616 mL | 2.3232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
